Dose intensification in acute myeloid leukaemia: Greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study

British Journal of Haematology

Volumn 94, Issue 1, 1996, Pages 89-98

  Rees, J K H ^a,c   Gray, R G ^b   Wheatley, K ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Cost benefit analysis; Dose intensity; Randomized controlled trial; Treatment duration

Indexed keywords

AMSACRINE; AZACITIDINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; PREDNISONE; TIOGUANINE; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030036637     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1769.x     Document Type: Article

References (27)

1. Archimbaud, E., Leblond, V., Michallet, M., Cordonnier, C., Fenaux, P., Travade, P., Dreyfus, F., Jaubert, J., Devaux, Y. & Fiere, D. (1991) Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood, 77, 1894-1900.
2. Bishop, J.F., Young, G.A., Szer, J., Matthews, J.P. & Page, A. (1992) Randomized trial of high dose cytosine arabinoside combination in induction in acute myeloid leukemia. Proceedings of the American Society of Clinical Oncology, 11, 260 (A848).
3. Bishop, J.F., Lowenthal, R.M., Joshua, D., Matthews, J.P., Todd, D., Cobcroft, R., Whiteside, M.G., Kronenberg, H., Ma, D., Dodds, A., Herrmann, R., Szer, J., Wolf, M.M. & Young, G., Australian Study Group (1990) Etoposide in acute non-lymphocytic leukemia. Blood, 75, 27-32.
4. Büchner, T., Hiddemann, W., Nowrousian, M., Aul, C., Koenig, H.-J., Straif, K., Hossfeld, D., Loeffler, H. & Heinecke, A. (1990a) Acute myeloid leukemia in elderly patients: full versus reduced dose induction chemotherapy: a randomized study by the AMLCG. Proceedings of the American Association of Cancer Research, 31, 194(A1156).
5. Büchner, T., Hiddemann, W. & Blasins, S. (1990b) Adult AML: the role of chemotherapy intensity and duration: two studies of the AML Cooperative Group. Haematology and Blood Transfusion, 33, 261-166.
6. Cassileth, P., Lynch, E., Hines, J.D., Oken, M.M., Mazza, J.J., Bennett, J.M., McGlave, P.B., Edelstein, M., Harrington, D.P. & O'Connell, M.J. (1992) Varying intensity of post remission therapy in acute myeloid leukemia. Blood, 79, 1924-1930.
7. Copplestone, J.A., Smith, A.G., Oscier, D.G. & Hamblin, T. (1986) True outlook in acute myeloblastic leukaemia. (Letter). Lancet, i, 1104.
8. Hill, I.D., Hill, R. & Holder, R.L. (1980) Fitting Johnson curves by moments. Journal of Applied Statistics, 7, 180-184.
9. Hoyle, C.F., de Bastos, M., Wheatley, K., Sherrington, P.D., Fischer, P.F., Rees, J.K.H., Gray, R.G. & Hayhoe, F.G.J. (1989) AML associated with previous cytotoxic therapy. MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. British Journal of Haematology, 72, 45-55.
10. Hoyle, C.F., Gray, R.G., Wheatley, K., Swirsky, D., de Bastos, M., Sherrington, P., Rees, J.K.H. & Hayhoe, F.G.J. (1991) Prognostic importance of Sudan Black positivity: a study of bone marrow slides from 1386 patients with acute myeloid leukaemia. British Journal of Haematology, 79, 398-407.
11. Kahn, S.B., Begg, C.B., Mazza, J.J., Bennett, J.M., Bonner, H. & Glick, J.H. (1984) Full dose versus attenuated dose daunorubicin. cytosine arabinoside, and 6-thioguanine in the treatment of acute non-lymphocytic leukemia in the elderly. Journal of Clinical Oncology, 2, 865-870.
12. Marucs, R.E., Catovsky, D., Goldman, J.M., Worsley, A.M. & Galton, D.A.G. (1984) Maintenance and consolidation therapy in AML. Lancet, i, 686-687.
13. Mayer, R.I., Davis, R.B., Schiffer, C.A., Berg, D.T., Powell, B.I., Schulman, P., Omura, G.A., Moore, J.O., McIntyre, O.R. & Frei, E. III (1994) Intensive post-remission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine, 331, 896-903.
14. Ohno, R., Kobayashi, T., Tanimoto, M. & Hiraoka, A. (1993) Longer intensive maintenance/intensification therapy prolongs disease-free survival (DFS) of adult AML. Proceedings of the American Society of Clinical Oncology, 12, 300 (A981).
15. Peto, R., Pike, M.C., Armitage, P., Breslow, N.K., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. & Smith, P.G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II. Analysis and examples. British Journal of Cancer, 35, 1-39.
16. Preisler, H.H. (1978) Failure of remission induction in acute myelocytic leukemia. Medical and Pediatric Oncology, 4, 275-276.
17. Preisler, H., Davis, R.B., Kirshner, J., Dupre, E., Richards, F., III. Hoagland, H.C., Kopel, S., Levy, R.N., Carey, R., Schulman, P., Gottlieb, A.J. & McIntyre, O.R. (1987) Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute non-lymphocytic leukemia: a Cancer and Leukemia Group B study. Blood, 69, 1441-1449.
18. Rai, K.R., Holland, J.F., Glidewell, O., Weinberg, V., Brunner, K., Obrecht, J.P., Preisler, H.D., Nawabi, I.W., Prager, D., Carey, R.W., Cooper, M.R., Haurani, F., Hutchinson, J.L., Silver, R.T., Falkson, G., Wiernik, P., Hoagland, H.C., Bloomfield, C.D., James, G.W., Gottlieb, A., Ramanan, S.V., Blom, J., Nissen, N.I., Bank, A., Ellison, R.R., Kung, F., Henry, P., McIntyre, O.R. & Kaan, S.K. (1981) Treatment of acute myelocytic leukemia: a study of Cancer and Leukemia Group B. Blood, 58, 1203-1212.
19. Rees, J.K.H. (1993) Aspects of treatment of acute myeloid leukaemia in adults. Current Opinion in Oncology, 5, 53-70.
20. Rees, J.K.H. & Gray, R. (1987) Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukaemia: MRC Ninth AML trial. Seminars in Oncology, 14, (Suppl. 1), 32-36.
21. Rees, J.K.H., Gray, R. & Hayhoe, F.G.J. (1987) The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia. Haematology and Blood Transfusion, 30, 35-37.
22. Rees, J.K.H., Gray, R., Swirsky, D. & Hayhoe, F.G.J. (1986) Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet, ii, 1236-1241.
23. Schiller, G., Gajewski, J., Nimers, S., Territo, M., Ho, W. Lee, M. & Champlin, R. (1992) A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. British Journal of Haematology, 81, 170-177.
24. The Toronto Leukaemia Study Group (1986) Results of chemotherapy from unselected patients with acute myeloblastic leukaemia: effect of exclusions on interpretation of results. Lancet, i, 786-788.
25. Weick, J., Kopecky, K., Appelbaum, F., Head, D., Elias, L., Kingsbury, L., Daniels, D., Balcerzak, S.P., Mills, G.M., Hynes, H.E., Coltman, C. & Grever, M. (1992) A randomized investigation of high-dose versus standard dose cytosine arahinoside with daunorubicin in patients with acute myelogenous leukemia. Proceedings of the American Society of Clinical Oncology. 11, 261 (A856).
26. White, S.J. & Freedman, L.S. (1978) Allocation of patients to treatment groups in a controlled clinical study, British Journal of Cancer, 37, 849-857.
27. Worsley, A.M., Catovsky, D., Goldman, J.M. & Galton, D.A.G., (1984) New combination chemotherapy for relapsed acute myeloid leukaemia. Lancet, i, 1232.